IntroductionIn December 2019, a novel epidemic of coronavirus pneumonia (COVID-19) was reported,and population-based studies had shown that cancer was a risk factor for death from COVID-19 infection. However, the molecular mechanism between COVID-19 and cancer remains indistinct. In this paper, we analyzed the nucleic acid sensor (DDX58) of SARS-CoV-2 virus, which is a significant gene related to virus infection. For purpose of clarifying the characteristics of DDX58 expression in malignant tumors, this study began to systematically analyze the DDX58 expression profile in the entire cancer type spectrum.MethodsUsing TCGA pan-cancer database and related data resources, we analyzed the expression, survival analysis, methylation expression, mutation status, microsatellite instability (MSI), immune related microenvironment, gene related network, function and drug sensitivity of DDX58.ResultsThe expression level of DDX58 mRNA in most cancers was higher than the expression level in normal tissues. Through TIMER algorithm mining, we found that DDX58 expression was closely related to various levels of immune infiltration in pan-cancer. The promoter methylation level of DDX58 was significantly increased in multiple cancers. In addition, abnormal expression of DDX58 was related to MSI and TMB in multiple cancers, and the most common type of genomic mutation was “mutation.” In the protein–protein interaction (PPI) network, we found that type I interferon, phagocytosis, ubiquitinase, and tumor pathways were significantly enriched. Finally, according to the expression of DDX58 indicated potential sensitive drugs such as Cediranib, VE−821, Itraconazole, JNJ−42756493, IWR−1, and Linsitinib.DiscussionIn conclusion, we had gained new insights into how DDX58 might contribute to tumor development, and DDX58 could be used as an immune-related biomarker and as a potential immunotherapeutic target for COVID-19 infected cancer patients.
BACKGROUND: The high incidence and mortality rates of gastric cancer posed a great challenge in its treatment. The principles of precision medicine called for improved staging diagnosis and prognosis assessment for better patient outcomes. Molecular staging of gastric cancer, based on the TCGA database, had gained significant attention. In this paper, we presented a novel approach to gastric cancer staging, utilizing the analysis of immunological signature gene sets expression across different samples, to construct a reliable prognostic model. Our findings provided a new tool for clinical management and treatment of gastric cancer. METHODS: RNA expression data for gastric cancer tissue samples and normal samples were downloaded from the official websites of The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). The immunological signature gene sets were obtained from the Gene Set Enrichment Analysis (GSEA) database. The RNA expression data was analyzed using various computational methods, including unsupervised clustering analysis, principal component analysis (PCA), and survival analysis. The unsupervised clustering analysis was used to divide the samples into three subtypes based on the expression of the immunological signature gene sets. PCA was performed to reduce the dimensionality of the data and identify the most informative genes. Survival analysis was used to identify the genes that were most strongly associated with patient prognosis. Based on the results of the analysis, we identified two gene sets that were strongly associated with patient prognosis. These gene sets were used to construct a prognostic model. The model was evaluated using various statistical methods, including receiver operating characteristic (ROC) curve analysis and Kaplan-Meier survival analysis. Finally, the biologically important functional pathways were analyzed using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and other databases. These analyses were used to identify the biological processes and pathways that were most strongly associated with the different subtypes of gastric cancer and the genes that were most important for patient prognosis. RESULTS: Based on the expression of immunological signature gene sets in different samples, we classified the samples into three subtypes and validated them in the GEO downloaded samples. By analyzing clinical information, we identified 34 prognosis-related gene sets. After screening, we selected two gene sets (GSE21546_UNSTIM_VS_ANTI_CD3_STIM_DP_THYMOCYTES_UP, HALLMARK_ANGIOGENESIS) for model construction. The models were able to accurately predict the prognosis of the samples. Functional analysis revealed that the PI3K-Akt pathway might play a key role. Finally, we performed drug sensitivity analysis on the five core genes (SPP1, COL3A1, FGFR1, APOH and THBD) and identified piperlongumine and cerulenin as highly sensitive drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.